Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Harvard Business School
Mallinckrodt
Merck
McKinsey

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,642,314

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,642,314
Title:Optimization of expression of parvoviral rep and cap proteins in insect cells
Abstract: The present invention relates to the improved production of recombinant parvoviral virions in insect cells. In particular, the invention relates to an improved process for the production of recombinant parvoviral virions in insect cells, wherein the full/empty parvoviral virion ratio is increased. The invention also relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral Rep proteins that increase the productivity of parvoviral vectors.
Inventor(s): Bakker; Andrew Christian (Almere, NL), Hermens; Wilhelmus Theodorus Johannes Maria Christiaan (Almere, NL), Noordman; Yvet (Utrecht, NL)
Assignee: Amsterdam Molecular Therapeutics (AMT) B.V. (NL)
Application Number:12/918,460
Patent Claims:1. A method for the production of a recombinant parvoviral virion, which comprises culturing an insect cell comprising one or more nucleic acid constructs which comprise: (a) a nucleotide sequence comprising a transgene that is flanked by at least one parvoviral inverted terminal repeat (ITR) nucleotide sequence; (b) a first expression cassette comprising a nucleotide sequence encoding at least one of parvoviral Rep proteins Rep78 and Rep68, which nucleotide sequence is operably linked to a first promoter that is capable of driving expression of the at least one of Rep78 and Rep68 proteins in the insect cell; and (c) a second expression cassette comprising a nucleotide sequence encoding a parvoviral capsid protein which is operably linked to a second promoter that is capable of driving expression of the capsid protein in the insect cell; under conditions conducive to the expression of the Rep protein and the capsid protein; wherein (i) the first and second expression cassettes are present on a single nucleic acid construct and are present in equimolar amounts in the insect cell, (ii) the ratio of the Rep78 and/or Rep68 protein expression to the capsid protein expression is regulated by one or more of the following: (A) the first promoter is stronger than the second promoter; (B) the presence of more and/or stronger enhancer elements in the first expression cassette as compared to the second expression cassette; (C) the nucleotide sequence encoding the Rep78 and/or Rep68 protein has a higher codon adaptation index as compared to the nucleotide sequence encoding the capsid protein; (D) temperature optimization of the Rep78 and/or Rep68 protein; and/or (E) a variant Rep78 and/or Rep68 protein with an alteration in the amino acid sequence as compared to the sequence of corresponding wild-type Rep78 and/or Rep68 protein, wherein the sequence alteration results in increased Rep78 and/or Rep68 protein function assessed as increased adeno-associated virus (AAV) production in the insect cell, resulting in expression of the Rep78 and/or Rep68 protein that is greater than expression of the capsid protein.

2. The method according to claim 1, wherein the nucleotide sequence of (c) comprises an open reading frame (ORF) comprising nucleotide sequences encoding the VP1, VP2 and VP3 capsid proteins.

3. The method according to claim 1, wherein the nucleotide sequence of (b)) comprises only one ORF comprising a nucleotide sequence encoding the Rep78 or the Rep 68 protein.

4. The method according to claim 2, wherein (i) at least one ORF comprising nucleotide sequences encoding VP1, VP2 or VP3 capsid proteins does not comprise an artificial intron, or (ii) at least one ORF comprising a nucleotide sequence encoding said at least one of Rep78 or Rep68 proteins does not comprise an artificial intron.

5. The method according to claim 4, wherein: (A) no ORF comprising nucleotide sequences encoding the VP1, VP2 and VP3 capsid proteins comprises an artificial intron; and/or (B) no ORF comprising nucleotide sequences encoding said at least one of the Rep78 and Rep68 proteins comprises an artificial intron.

6. The method according to claim 1, wherein the first promoter or the second promoter is selected from the group consisting of (a) a PolH promoter, (b) p10 promoter, (c) a basic promoter, (d) an inducible promoter, (e) an E1 promoter, and (f) a deltaE1 promoter.

7. The method according to claim 6, wherein the first promoter is: (a) a PolH promoter, (b) p10 promoter or (c) basic promoter, and the second promoter is: (d) a deltaE1 promoter or (e) an E1 promoter.

8. The method according to claim 1, wherein the first expression cassette comprises at least one baculovirus enhancer element and/or at least one ecdysone responsive element.

9. The method according to claim 8, wherein the enhancer element is selected from the group consisting of hr1, hr2, hr3, hr4 and hr5.

10. The method according to claim 1, wherein the parvoviral ITR sequence, the parvoviral Rep78 and/or Rep68 protein and/or the parvoviral capsid protein are from an AAV.

11. A nucleic acid construct comprising a first and a second expression cassette as defined in claim 1, wherein: (a) the first promoter is a p10 promoter and the second promoter is a 4.times.Hsp27 EcRE+minimal Hsp70 promoter; (b) the first promoter is a PolH promoter and the second promoter is a deltaE1 or an E1 promoter; or (c) the first promoter is a p10 promoter and the second promoter is a deltaE1 or an E1 promoter; wherein the first expression cassette optionally comprises an enhancer element.

12. The method according to claim 1, further comprising a step of recovering the recombinant parvoviral virion from the culture.

13. A kit comprising (a) a first nucleic acid construct comprising: (i) a first expression cassette comprising a nucleotide sequence encoding at least one of a parvoviral Rep protein Rep78 and Rep68 which is operably linked to a first promoter that is capable of driving expression of the Rep78 or Rep68 protein in a host insect cell; and (ii) a second expression cassette comprising a nucleotide sequence encoding a parvoviral capsid protein which is operably linked to a second promoter that is capable of driving expression of the capsid protein in the insect cell; wherein (A) the first promoter is or stronger than the second promoter; (B) the first expression cassette comprises more and/or stronger enhancer elements as compared to the second expression cassette; (C) the nucleotide sequence encoding the Rep78 and/or Rep68 protein has a higher codon adaptation index as compared to the nucleotide sequence encoding the capsid protein; (D) the Rep78 and/or Rep68 protein is temperature optimized; and/or (E) the Rep78 and/or Rep68 protein is a variant with an alteration in the amino acid sequence as compared to the sequence of corresponding wild-type Rep78 and/or Rep68 protein, wherein the sequence alteration results in increased Rep78 and/or Rep68 protein function assessed as increased adeno-associated virus (AAV) production in the insect cell, such that, when expressed in the insect cell, expression of the Rep78 and/or Rep68 protein is greater than expression of the capsid protein, and (b) a second nucleic acid construct comprising a nucleotide sequence encoding a multiple cloning site for a transgene, which site is flanked by at least one parvoviral ITR nucleotide sequence, and which transgene is operably linked to a promoter capable of driving its expression in a host insect cell.

14. An insect cell comprising one or more nucleic acid constructs, which comprise: (a) a nucleotide sequence comprising a transgene that is flanked by at least one parvoviral ITR nucleotide sequence; (b) a first expression cassette comprising a nucleotide sequence encoding at least one of parvoviral Rep proteins Rep78 and Rep68, which nucleotide sequence is operably linked to a first promoter that is capable of driving expression of the at least one of Rep78 and Rep68 proteins in the insect cell; and (c) a second expression cassette comprising a nucleotide sequence encoding a parvoviral capsid protein which is operably linked to a second promoter that is capable of driving expression of the capsid protein in the insect cell; wherein (i) the first and second expression cassettes are present on a single nucleic acid construct and are present in equimolar amounts in the cell; and (ii) the ratio of Rep78 and/or Rep68 protein expression to capsid protein expression in said cell is regulated by one or more of the following: (A) the first promoter is or stronger than the second promoter; (B) the presence of more and/or stronger enhancer elements in the first expression cassette as compared to the second expression cassette; (C) the nucleotide sequence encoding the Rep78 and/or Rep68 protein has a higher codon adaptation index as compared to the nucleotide sequence encoding the capsid protein; (D) temperature optimization of the Rep78 and/or Rep68 protein; and/or (E) a variant Rep78 and/or Rep68 protein with an alteration in the amino acid sequence as compared to the sequence of corresponding wild-type Rep78 and/or Rep68 protein, wherein the sequence alteration results in increased Rep78 and/or Rep68 protein function assessed as increased AAV production in the cell such that expression of Rep78 and/or Rep68 protein is greater than expression of the capsid protein.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
08151634Feb 19, 2008
PCT Information
PCT FiledFebruary 19, 2009PCT Application Number:PCT/NL2009/050076
PCT Publication Date:August 27, 2009PCT Publication Number:WO2009/104964

Details for Patent 8,642,314

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Amsterdam Molecular Therapeutics (AMT) B.V. (NL) 2028-02-19 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Amsterdam Molecular Therapeutics (AMT) B.V. (NL) 2028-02-19 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Amsterdam Molecular Therapeutics (AMT) B.V. (NL) 2028-02-19 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
Express Scripts
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.